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Abstract
Background: Osteosarcoma is a bone-forming tumor of mesenchymal origin that presents a clinical pattern that is
consistent with the cancer stem cell model. Cells with stem-like properties (CSCs) have been identified in several
tumors and hypothesized as the responsible for the relative resistance to therapy and tumor relapses. In this study,
we aimed to identify and characterize CSCs populations in a human osteosarcoma cell line and to explore their
role in the responsiveness to conventional therapies.
Methods: CSCs were isolated from the human MNNG/HOS cell line using the sphere formation assay and
characterized in terms of self-renewal, mesenchymal stem cell properties, expression of pluripotency markers and
ABC transporters, metabolic activity and tumorigenicity. Cell’s sensitivity to conventional chemotherapeutic agents
and to irradiation was analyzed and related with cell cycle-induced alterations and apoptosis.
Results: The isolated CSCs were found to possess self-renewal and multipotential differentiation capabilities,
express markers of pluripotent embryonic stem cells Oct4 and Nanog and the ABC transporters P-glycoprotein and
BCRP, exhibit low metabolic activity and induce tumors in athymic mice. Compared with parental MNNG/HOS cells,
CSCs were relatively more resistant to both chemotherapy and irradiation. None of the treatments have induced
significant cell-cycle alterations and apoptosis in CSCs.
Conclusions: MNNG/HOS osteosarcoma cells contain a stem-like cell population relatively resistant to conventional
chemotherapeutic agents and irradiation. This resistant phenotype appears to be related with some stem features,
namely the high expression of the drug efflux transporters P-glycoprotein and BCRP and their quiescent nature,
which may provide a biological basis for resistance to therapy and recurrence commonly observed in
osteosarcoma.
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Background
Osteosarcoma is the most common malignant primary
bone tumor comprising 20% of all bone tumors and
about 5% of pediatric tumors overall [1]. Significant
improvements in patient survival rates have been
achieved in recent years, largely due to multimodal ther-
apeutic approaches combining high-dose chemotherapy
and surgical resection [2]. Radiotherapy, although not a
primary choice for treatment, is frequently applied for
local control in patients for whom surgical resection
with sufficient margins is not achievable [3,4]. Despite
these advances, the overall relapse free-survival rate over
5-years has stagnated at approximately 65% to 75% and
the intensification of chemotherapy regimens has
improved histological response but not survival [5,6].
There is increasing evidence that tumors are hierarchi-
cally organized and sustained by a subset of cells with
attributes of stem cells that are refractory to conven-
tional therapies [7]. These cells, referred to as cancer
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cells, share several characteristics with embryonic and
somatic stem cells including self-renewal and differentia-
tion abilities, and represent a small fraction of the cellu-
lar population of a tumor [8].
Recent reports have found that tumor cells expressing
stem markers are able to initiate solid tumors in immu-
nodeficient mice recapitulating the heterogeneity of the
original tumors, supporting the theory that residual
undifferentiated cells contain the complete genetic pro-
grams necessary to initiate tumorigenesis and sustain
the growth of the tumor bulk [9]. Studies performed in
glioblastoma and breast cancer support the theory that
CSCs have innate survival advantages compared with
more differentiated cells, allowing them to survive after
therapy and regenerate the tumor [10]. This phenotype
appears to be related with properties they share with
normal stem cells, such as the higher capacity for DNA
repair, quiescent status and the overexpression of ATP-
binding cassette drug transporters including P-glycopro-
tein (Pgp) and the breast cancer resistance protein
(BCRP) [11,12]. These transmembrane proteins behave
as drug efflux pumps of most chemotherapeutic agents
preventing their intracellular accumulation at toxic con-
centrations [13]. Since Pgp and BCRP recognize most
conventional chemotherapeutic drugs as transport sub-
strates, it is likely that they contribute largely to a che-
motherapy-resistant phenotype when expressed by CSCs
[12]. The relative quiescence and slow cycling rate of
CSCs render them refractory to therapies that rely on
cell cycle kinetics to induce lethal cellular damage in
highly proliferative cells [14]. This was observed in leu-
kemia stem cells isolated from acute myelogenous leuke-
mia, which, due to their quiescence, proved to be less
sensitive to chemotherapy [15].
Recently, a subpopulation of cancer cells with stem-like
properties was identified in bone sarcomas [16,17]. These
cells were found to express surface markers of mesenchy-
mal stem cells (MSCs) as well as ability to differentiate
along mesenchymal lineages (osteogenic, adipogenic and
chondrogenic), which suggest that sarcomas arise from
cells at least as primitive as MSCs that undergo onco-
genic transformation and contain a subpopulation of
cells with attributes of stem cells. The evidence of such
cells in bone sarcomas may provide a rational explana-
tion for the recurrence often observed in such aggressive
tumors and help us to understand why this tumor is so
difficult to eradicate. Although several retrospective stu-
dies have identified dose intensity as a potential determi-
nant factor in survival of osteosarcoma patients, the
results of the third European Osteosarcoma Intergroup
(EOI) randomized controlled trial in osteosarcoma
showed that the increment in dose intensity, while
improving histologic response, did not translate into a
demonstrable patient benefit in overall survival or pro-
gression-free survival [6]. Although intensified che-
motherapy kills cancer cells and shrinks the tumors, it is
likely that a minority of cells escapes treatments and has
tumor initiating ability. If these are truly CSCs and given
the specific stem cell features, the current therapeutic
approaches may not address this subset of cells leading
to relapse, which emphasizes the need to develop more
effective therapeutic strategies targeting CSCs [18].
Therefore, a better understanding of CSCs’ response to
conventional therapies is essential to understand the bio-
logical consequences of their existence in clinical
response and to provide targets for new CSC-directed
therapies. In the present study, we aimed to evaluate the
role of osteosarcoma cells with stem features in the
responsiveness to conventional therapies including the
current chemotherapeutic agents recommended by Eur-
opean and American Osteosarcoma group (EURAMOS-
1) and to ionizing irradiation.
We have identified a subpopulation of cells with stem-
like properties in a human osteosarcoma cell line that is
relatively resistant to both conventional chemo- and
radiotherapy. This resistant phenotype appears to be
related with stem features, namely the high expression
of drug transporters and quiescent status. Based on
these observations, we believe that CSCs play a critical
role in determining the response of osteosarcoma
patients to therapy and should be considered when
designing new anti-cancer therapies.
Methods
Cell culture and sphere-forming assay
Human MNNG/HOS osteosarcoma cell line was pur-
chased from the American Type Culture Collection
(Rockville, MD) and was cultured in RPMI 1640 medium
(Gibco, Scotland, UK) supplemented with 10% heat inac-
tivated fetal bovine serum (FBS) at 37°C in a humidified
incubator with 95% air and 5% CO2. The sphere forming
assay was performed as described previously by Gibbs et
al. with minor modifications [16]. After reaching 60-80%
confluence, cells were harvested and plated at a density
of 60,000 cells/well on 6-well poly-HEMA-coated plates
(Sigma, St Louis, USA) in serum-free DMEM/F12 med-
ium (Sigma) with 1% of methylcellulose (Sigma) supple-
mented with 1% penicillin/streptomycin (Gibco), 20 nM
progesterone (Sigma), 100 μMp u t r e s c i n e( S i g m a ) ,1 %
insulin-transferrin-selenium A supplement (Gibco),
10 ng/ml basic fibroblast growth factor (bFGF, Peprotech
EC, London, UK) and 10 ng/ml human recombinant epi-
dermal growth factor (EGF, Sigma). Fresh aliquots of
growth factors were added twice a week. After 7 days of
culturing, the formed cellular spheres (sarcospheres)
were collected, dissociated with accutase and re-seeded
again in stressful growth conditions for formation of
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three times to evaluate the self-renewing capacity of the
spherical clones in anchorage-independent conditions.
The total number of spherical colonies obtained at each
passage was quantitated under an inverted phase contrast
microscope. The sphere-forming efficiency at each pas-
sage was calculated by dividing the number of spheres
formed by the total number of cells seeded and expressed
as a percentage.
A third generation sphere culture was transferred to
adherent plates and allowed to grow in monolayer in
culture medium supplemented with 10% FBS without
growth factors. This sphere-derived monolayer culture is
referred to as SAR-OS cells and was expanded and used
in some subsequent studies to verify if these cells
derived directly from sarcospheres acquired the same
biological behavior as parental MNNG/HOS cells.
Flow cytometry analysis of mesenchymal stem cell
markers
The immunophenotype of sarcospheres was analyzed for
the expression of surface antigens associated with MSCs
according to the International Society for Cellular Therapy
(ISCT) [19]. Cells derived from monolayer cultures and 7-
day old sarcospheres were enzymatically dissociated with
Trypsin-EDTA and Accutase (Sigma), respectively, and re-
suspended in phosphate-buffered saline solution (PBS).
Single-cell suspensions (1 × 10
6/ml) were then incubated
with PE-conjugated anti-CD105 (Immunostep), PE-conju-
gated anti-CD73 (BD Pharmingen), APC-conjugated anti-
90 (BD Pharmingen) and PO-conjugated anti-CD13 (BD
Pharmingen). Negative control staining was performed
with the APCH7-conjugated anti-CD45 (BD Pharmingen),
PB-conjugated anti-CD11b (BD Pharmingen), PE-Cy7-
conjugated anti-CD19 (eBioscience), PerCP-Cy5.5-conju-
gated anti-CD34 (BD Pharmingen) and FITC-conjugated
anti-HLA-DR (eBioscience). Data were acquired on a
FACSCalibur flow cytometer (Beckton-Dickinson, San
Diego, CA, USA) and analyzed using the CellQuest soft-
ware (BD Biosciences).
Multilineage differentiation studies
MNNG/HOS cells and clonally-derived sarcospheres were
induced to differentiate towards mesenchymal lineages
(osteoblasts, chondrocytes and adipocytes) using the
STEMPRO
® differentiation kits (Gibco) according to the
manufacturer’s instructions. In brief, after expansion in
MSC growth medium (low glucose DMEM supplemented
with 10% of MSC qualified FBS, 2 mM glutamine and 1%
penicillin/streptomycin), cells were seeded into StemPro
®
Osteogenesis, Adipogenesis or Chondrogenesis Differen-
tiation medium in 12-well plates. The induction medium
was changed every 3 to 4 days during the incubation per-
iod. Osteogenic differentiation was assessed after 21 days
of incubation. Cells were fixed with 4% formaldehyde and
stained with 2% Alizarin Red S (Sigma) to identify the for-
mation of calcium deposits. To visualize adipogenic differ-
entiation, cultures were fixed with 4% formaldehyde and
stained with Oil Red O (Sigma, 3 mg Oil Red O/ml 60%
isopropanol) after 14 days in adipogenic induction med-
ium. Chondrogenic differentiation was monitored after 16
days by staining micromass pellet cultures with 1% Alcian
Blue (Sigma) for proteoglycan matrix production. Images
were taken using an inverted fluorescence microscope
(Nikon, Eclipse TS 100) and Motic Images Advanced 3.2
software.
Western blot analysis
Cells were lysed in a RIPA buffer containing protease and
phosphatase inhibitors (Roche, Germany). Protein concen-
tration was determined using the BCA protein assay kit
(Merck, Germany). About 40 μg of total extract protein
from MNNG/HOS cells and sarcospheres were separated
by SDS-PAGE and then electrotransferred to activated
polyvinylidene difluoride membranes. Non-specific protein
binding was blocked by incubating the membranes for 1 h
with 5% non-fat dry milk in 0.1% TBS-T. Membranes
were incubated for 2 h at room temperature with primary
antibodies at a dilution of 1:1000 for human monoclonal
anti-Oct4 (Cell Signaling), 1:1000 for human monoclonal
anti-Nanog (Cell Signaling), 1:150 for human monoclonal
anti-Pgp (Calbiochem) and 1:250 for human monoclonal
anti-BCRP (Millipore). The membranes were then washed
in TBS-T and incubated for 1 h in horseradish peroxidase-
conjugated secondary anti-rabbit or anti-mouse antibody
at a dilution of 1:20000. The proteins were visualized by
chemifluorescence (ECF™ Western Blotting Reagent
Pack, GE Lifesciences, Pittsburg, PA) using Typhoon™
FLA 9000 imager. Fold change in protein expression was
expressed as a ratio calculated by dividing the specific pro-
tein band density by the b-actin band density and then
normalized to the control.
Animal care
Six-week-old male Balb/c nude mice were obtained from
Charles River Laboratories and housed under pathogen-
free conditions in individual ventilated cages. Sterile food
and water were provided ad libitum. The animal experi-
ments were performed according to the local and inter-
national guidelines on animal experimentation and were
approved by the Institutional Ethics Committee of the
Faculty of Medicine of University of Coimbra for animal
care and use (Approval ID:38-CE-2011, additional file 1).
Tumorigenic potential of sarcospheres
The tumorigenic potential of sarcospheres was assessed
through their ability to generate tumors in immunocom-
promised mice. One hundred thousand dissociated cells
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cells (MNNG/HOS) were re-suspended in 200 μlo fP B S
and injected subcutaneously (s.c.) into opposite flanks.
Tumors’ development was monitored weekly for up to
6 weeks and the volume was calculated by V = (length ×
width
2)/2. The animals were sacrificed by cervical disloca-
tion when the tumors reached 1.5 cm
3.
Metabolic activity
The metabolic activity of sarcospheres and of adherent
cells was measured based on cellular uptake of the glu-
cose analogue [
18F]-2-fluoro-2-deoxy-D-glucose (FDG).
FDG was provided by the Institute for Nuclear Sciences
Applied to Health (ICNAS), Portugal. Single-cell suspen-
sions (2 × 10
6 cells/ml) derived from spherical clones
and of monolayer cultures were incubated with 0.75
MBq/ml of FDG at 37°C. At 15, 30 and 60 min samples
of 200 μl were taken and transferred to microcentrifuge
tubes containing 500 μl of ice-cold PBS and washed
twice in PBS. Cell pellets and supernatants were assayed
for g-radioactivity in a well-type sodium iodide g-coun-
ter (SR3, Nuclear Enterprises, Reading, UK) within the
18F-sensitivity energy window set as 20%. Results are
reported as the percentage of cell-radioactivity asso-
ciated to the total radioactivity added and normalized
per million of cells.
Drug cytotoxicity assays
We analyzed the chemosensitivity of both sarcospheres
and adherent cells (MNNG/HOS and SAR-OS) to the
chemotherapeutic agents recommended by the EURA-
MOS -1 protocol for the treatment of OS that includes
doxorubicin (DOX, DOXO-cell
®, Portugal), cisplatin
(CIS, Teva Pharma, Portugal) and methotrexate (MTX,
Teva Pharma). Cell viability was analyzed using the 3-
(4,5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bro-
mide (MTT, Sigma) assay. Dissociated 7-day old sarco-
spheres and adherent cells (MNNG/HOS and SAR-OS)
were seeded in 24-well plates (25 × 10
3 cells/well),
allowed to attach overnight and then subsequently trea-
ted with increasing concentrations of DOX (0.001 -
60 μM), CIS (0.001 - 80 μM) and MTX (0.001 - 1000
μM). Forty-eight hours after treatment, 200 μlo fM T T
solution (0.5 mg/ml) was added to each well, and incuba-
tion continued for an additional 4 hours. Formed blue
formazan crystals were dissolved by adding 200 μLo f
acidified isopropanol (0.04 N HCl). The solubilized pro-
ducts were transferred to 96 well-plates and the absor-
bance was read in a microplate reader (Synergy™ HT,
Biotek Instruments) at 570 nm using a 620 nm filter as
reference. Cytotoxicity was expressed as the percentage
of cells surviving in relation to untreated cells. The drug
concentration required to inhibit growth by 50% (IC50)
was estimated with Origin 8.0 (OriginLab Corporation),
using the dose-response equation:
y=A 1 +
A1 − A2
1+1 0 (Logx0−x)p
where A1 and A2 are the amplitude of the baseline
and maximum response, respectively, x0 is the IC50 and
p is the slope.
Reversal of resistance to DOX
I no r d e rt oe x p l o r ew h e t h e rP g pa n dB C R Pa r ef u n c -
tionally active and can account for the higher chemore-
sistance of sarcospheres, we evaluated the effects of
verapamil (VER), a potent inhibitor of Pgp and BCRP
on reversal of DOX resistance. DOX is a transport sub-
strate of both Pgp and BCRP. Cells dissociated from sar-
cospheres and from adherent cells, MNNG/HOS and
SAR-OS, were incubated with increasing concentrations
of DOX in the presence of non-toxic concentrations of
VER (10 μM) during 48 h. The IC50 value was calcu-
lated as described above.
Irradiation assay
Single-cell suspensions of sarcospheres and of adherent
cultures (MNNG/HOS and SAR-OS) were placed in
plastic tubes filled with culture medium and irradiated
with single doses of 2, 4, 6, 8, 10, 15 and 20 Gy in a lin-
ear accelerator (Varian Clinac 600 C) at a dose rate of
2.70 Gy/min. To assure that cells received a uniform
radiation exposure, tubes containing cells were sub-
mersed in water in an acrylic container positioned with
its long axis parallel to the central axis of the beam.
Corresponding controls were sham-irradiated. After irra-
diation, cells were seeded in 24-well plates at a density
of 10 × 10
3 cells/well for adherent cells and 50 × 10
3
cells for sarcosphere-derived cells and cultured for 7
days. Cell survival was determined using the MTT col-
orimetric assay. Surviving fractions for each irradiation
dose were normalized to the values of sham-irradiated
corresponding controls. Cell survival curves were fitted
in Origin 8.0, using the linear-quadratic model (LQM),
according to the equation:
SF=e−αD−βD2
in which SF is the surviving fraction at a dose D, a is
the log cells killed per Gy of the linear component and
is regarded as an estimate of the initial irreparable DNA
damage (double-strand breaks, DSB), and b is the log
cells killed per Gy
2 of the quadratic component and
represents the capacity for DNA repair of sub-lethal
damage (single-strand breaks, SSB). The median lethal
dose (LD50) corresponding to the irradiation dose that
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intrinsic radiosensitivity for each cell line.
Reactive oxygen species formation assay
The formation of reactive oxygen species (ROS) induced
by irradiation was assayed using the fluorescent dye 2’7’-
dichlorofluorescein diacetate (H2DCF-DA, Gibco)
according to the manufacturer instructions. In brief, sin-
gle-cell suspensions were incubated with 10 μM
H2DCF-DA for 30 min in the dark. The cells were then
washed to remove the loading buffer and allowed to
recover in a pre-warmed growth medium. Before irra-
diation, the cells were re-suspended in PBS and irra-
diated as indicated above. A total of 50 × 10
3cells/well
was transferred to a black 96-well plate and the fluores-
cence intensity was measured in a fluorescence micro-
plate reader (Synergy™ HT, Biotek Instruments) in
triplicate wells (excitation: 498 nm, emission: 530 nm).
Fluorescence intensity was normalized to the fluores-
cence values of non-irradiated cells.
Cell cycle analysis and apoptosis
Cell cycle distribution of both adherent and sphere-
forming cells was analyzed by flow cytometry at 48 h
after treatment with chemotherapeutic agents and irra-
diation. Disaggregated cell suspensions were fixed with
75% ice-cold ethanol overnight and then incubated with
10 μg/ml propidium iodide (Sigma) in the presence of
500 μg/ml RNase (Sigma) for 60 min. Cell cycle data
were collected on BD FACSCalibur Flow Cytometer
(San Jose, CA) and analyzed using CellQuest data hand-
ling program. At least 10,000 events were acquired per
experiment. The flow cytometer was calibrated with
fluorescent standard microbeads (CaliBRITE Beads; BD
Biosciences) for accurate instrument setting. Apoptosis
was detected by nuclear Hoechst-33342 staining. After
treatments, cells were permeabilized, fixed with ice-cold
methanol-acetone (1:1), washed with PBS and then incu-
bated with the DNA-specific dye Hoechst-33342 (Sigma,
5 μg/ml). The coverslips were mounted onto slides
using Vectashield Medium and visualized under a fluor-
escence microscope (Zeiss LSM, 510 Meta) to examine
the degree of nuclear fragmentation and chromatin
condensation.
Statistical analysis
Statistical analysis was performed with Statistical Package
for the Social Sciences (SPSS) software (version 17; SPSS,
Inc., Chicago, IL). Multiple comparisons between the
three cells types were performed using the non-parametric
Kruskal-Wallis test. The Mann-Whitney non-parametric
test was applied to determine the difference between two
groups. Level of significance was set at p < 0.05.
Results
Spherical colonies formation and self-renewal
To assess the presence of putative CSCs in osteosarcoma,
MNNG/HOS cells (Figure 1A) were allowed to growth in
serum-free medium in anchorage-independent condi-
tions. After 2 days of culture, cells started to form float-
ing spherical colony-like structures that continued to
grow in size until they reached 50-100 μm in diameter
(Figure 1B) at the end of the first week. The sphere-form-
ing efficiency determined by the number of colonies
formed per 60,000 total MNNG/HOS cells plated was of
5.3 ± 0.4% (n = 3). A second generation of sarcospheres
was formed with an efficiency of 4.7 ± 0.7% (n = 3), yield-
ing a stem cell frequency similar to that of the primary
sphere formation assay (Figure 1C). This was further
observed in a third round of sphere-forming assay, which
demonstrates the ability of sarcospheres to self-renew
under growth-constraining conditions. After plating in
adherent conditions cells migrated from the colonies and
started to adhere to the bottom of the flasks acquiring
spindle-shaped morphology similar to the adherent
MNNG/HOS cells (Figure 1D). Sarcospheres of the third
generation, also termed as CSCs, were used in all subse-
quent experiments.
Sarcospheres have attributes of mesenchymal stem cells
markers and show trilineage differentiation potential
Because osteosarcoma originates from primitive mesench-
ymal bone-forming cells, third generation spheres were
screened for the expression of cell surface proteins asso-
ciated with MSCs by flow cytometry, according to the
ISCT recommendations. The analysis revealed that sarco-
sphere-derived cells were positive for MSCs markers
CD73, CD90, CD13 and CD105 (Figure 2A), and were
negative for CD34, CD44, CD11b, CD19 and HLA-DR
(data not shown). The lack of expression of these markers
excludes hematopoietic progenitors and endothelial cells
that are likely to be found in a MSC culture. There was no
significant differential expression of these markers
between sarcospheres and MNNG/HOS cells (Figure 2A).
The multipotency of isolated sarcospheres was evalu-
ated through their ability to differentiate towards osteo-
genic, chondrogenic and adipogenic lineages upon
culturing in specific differentiating conditions. Molecular
markers of either osteogenic, chondrogenic or adipogenic
commitment are shown in Figure 2B. Discrete foci of
matrix mineralization were visualized by Alizarin Red S
staining in cells cultured in osteogenic medium at 21
days. The differentiation in chondrogenic lineage was
demonstrated by the intense Alcian Blue staining by day
16 under chondrogenic conditions. Visible Oil Red O-
positive droplets containing-cells were seen at 14 days in
adipogenic differentiating medium. Parental MNNG/
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to differentiate towards adipocytes or chondrocytes (data
not shown).
Sarcospheres are enriched for stem cell specific
transcription factors and drug efflux transporters
We investigated whether sarcospheres are enriched for
the expression of the transcription factors Oct4 and
Nanog, which are required for maintaining the pluripo-
tency and self-renewal capacity of embryonic stem cells.
Our western blot analysis revealed a 3.7-fold increase in
O c t 4p r o t e i ne x p r e s s i o ni ns a r c o s p h e r e sc o m p a r e dt o
parental MNNG/HOS cells (Figure 2C). The expression
levels of Nanog were modest, but significantly increased
(1.7-fold) in sarcospheres compared with MNNG/HOS
cells. Another characteristic of stem-like cells is the
enhanced expression of the drug efflux transporters P-
glycoprotein and BCRP that protects them from damages
induced by cytotoxic agents. Comparative analysis
revealed a significant (p < 0.05) 17-fold increased expres-
sion of Pgp and a 5.0-fold increase of BCRP in sarco-
spheres in relation to MNNG/HOS cells (Figure 2C). To
further confirm if sarcospheres generate a differentiated
progeny similar to the parental cells, we analyzed the
expression levels of both stem cell markers Oct4 and
Nanog and of ABC-related transporters in SAR-OS cells.
As shown in Figure 2C, the four proteins that were upre-
gulated in sarcospheres, returned to the expression levels
found in parental MNNG/HOS cells, indicating that sar-
cospheres upon being cultured under differentiating con-
ditions re-acquire the phenotype of differentiated
parental cells.
Sarcospheres have enhanced tumorigenic ability
Other characteristic that defines CSCs is their ability to
initiate tumors in vivo. To verify if sarcospheres have
enhanced tumorigenicity when compared with parental
cells, equal numbers of cells (1 × 10
5) derived from sarco-
spheres and of MNNG/HOS culture were injected subcu-
taneously in opposite flanks of nude mice (n = 3). Both
cell fractions had the capacity to form tumors; however
the size of the tumors derived from sarcospheres were
significantly larger when compared with that from
MNNG/HOS cells and started growing earlier. After 3
weeks the sarcosphere-derived tumors had an average
volume of 158.3 ± 2.2 mm
3, in contrast to the 22.8 ± 9.3
mm
3 of MNNG/HOS-derived tumors (Figure 2D). These
results support the hypothesis that sarcospheres are
enriched in stem-like cells with enhanced tumorigenic
potential and that parental MNNG/HOS cells contain a
Figure 1 Osteosarcoma cells form sarcospheres in serum-free medium and grow in an anchorage-independent manner. (A) Monolayer
culture of parental MNNG/HOS cell line. (B) Spherical colonies (sarcospheres) generated from single-cell suspensions of MNNG/HOS cells cultured
in serum-free medium supplemented with growth factors in non-adherent conditions after 10 days. (C) Formation of secondary sarcospheres (7
days) derived from dissociated primary spheres. (D) Adherent expansion of a sarcosphere removed from the suspension culture and
reintroduced into adherent conditions. (Original magnification: 200×).
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analysis of MSCs’ surface markers in sarcospheres and MNNG/HOS cells. Both cells evidenced a strong positivity for CD73, CD90, CD13 and
CD105. Unstained cells (grey) appear at the lower left quadrant as a negative fluorescence control. (B) Stainings demonstrating the differentiation
potential of CSCs into mesenchymal lineages: osteoblasts (Alizarin Red), chondroblasts (Alcian Blue) and adipocytes (Oil Red), after incubation in
osteogenic, chondrogenic or adipogenic inducing medium during 21, 16 and 14 days, respectively. (C) Western blot analysis of Oct4, Nanog, P-
glycoprotein and BCRP in CSCs, SAR-OS and MNNG/HOS cells. b-actin was blotted as the loading control. The bottom panel shows the
quantitative analysis of proteins (normalized to b-actin) expressed as a ratio of the levels found in MNNG/HOS cells, set as 1 for all proteins. The
expression of all analyzed proteins is significantly enhanced in CSCs as compared with parental MNNG/HOS cells. The sphere-derived monolayer
culture (SAR-OS) showed similar protein expression profiles to those observed in MNNG/HOS cells. Data represents mean ± standard error of the
mean (SEM) of three independent experiments. *Significantly different from MNNG/HOS cells (p < 0.05). (D) Tumorigenic potential of CSCs. Balb/
c nude mice were s.c injected with 1 × 10
5 of CSCs in the right flank and of MNNG/HOS in the left flank. Tumor growth was monitored every
week. Representative image showed a CSC-derived tumor with a volume 7-fold higher to that induced by MNNG/HOS cells.
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most of them are non-stem cells.
Metabolic activity of sarcospheres during differentiation
The metabolic activity of sarcospheres was estimated
based on the cellular uptake of FDG and compared with
that of their adherent counterparts. FDG uptake reflects
both transport and phosphorylation of glucose by viable
cells and is a well-established method for assessing the
metabolic activity in tumor cells. A relatively low uptake
of FDG was observed in sarcospheres as compared with
that in MNNG/HOS and SAR-OS cells (Figure 3A,
Table 1). At 60 minutes, the mean value of FDG uptake
in sarcospheres (2.94 ± 1.33%) was about 4-fold lower
than that in MNNG/HOS cells (11.57 ± 3.55%) and
SAR-OS (11.27 ± 3.62%). This relatively lower accumu-
lation of FDG in sarcospheres could be related with the
quiescent status of these cells. The metabolic changes
occurring under differentiation conditions were analyzed
through the measurements of cellular FDG uptake at
different periods of incubation in serum-containing
medium under adherent conditions. Upon transference
to adherent conditions, it was observed a progressive
increase in the cellular uptake of FDG within the incu-
bation period (Figure 3B, Table 2). After 19 days of cul-
turing, cells accumulated FDG with a similar pattern to
the observed in the parental MNNG/HOS cells.
Increased survival of sarcospheres following chemo- and
radiotherapy, and reversal of resistance to DOX
Sarcospheres and both adherent MNNG/HOS and SAR-
OS cells were assayed for their sensitivity to chemother-
apeutic agents and irradiation. Cell survival response
following all treatments was measured using the MTT
viability assay.
Dose-response curves of sarcosphere and adherent
cells treated with DOX, CIS and MTX are presented in
Figure 4. All drugs inhibited cell viability in a dose-
dependent manner, but sarcospheres were found to be
more resistant as compared with their adherent counter-
parts. The mean IC50 values of all tested drugs in sarco-
spheres were significantly higher (Table 3) than those
calculated in adherent cells. The differentiated progeny
of sarcospheres (SAR-OS) displayed a drug sensitivity
pattern similar to that of parental MNNG/HOS cells, as
depicted in Figure 4 and Table 3, for the three drugs
tested.
Reversal of resistance to DOX, by inhibition of Pgp
and BCRP drug efflux pumps, was achieved using 10
μM of verapamil. Co-incubation with VER 10 μM,
increased the sensitivity of sarcospheres to DOX and
had no significant effects in adherent MNNG/HOS or
SAR-OS cells, as illustrated in Figure 5. The IC50 of
DOX in sarcospheres decreased significantly (p < 0.05)
Figure 3 FDG uptake of CSCs and of adherent cells.S i n g l ec e l l
suspensions were incubated with 0.75 MBq/mL of FDG at 37°C. At
15, 30 and 60 min, samples were collected and radioactivity of the
pellet and supernatant was measured in a radioisotope calibrator
well counter. Results are reported as the percentage of cell
radioactivity associated with the total radioactivity added,
normalized per million of cells. (A) Uptake of FDG in CSCs, SAR-OS
and MNNG/HOS cells. At 60 min, the cellular uptake of FDG in CSCs
was of 4-fold lower than that in both adherent MNNG/HOS and
SAR-OS cells. (B) Uptake of FDG during differentiation of CSCs. FDG
uptake increased progressively with the number of days of culture
of CSCs in differentiating conditions, acquiring a metabolic profile
similar to that of MNNG/HOS cells after 19 days. Data are shown as
the mean ± standard deviation of four (n = 4, A) and three (n = 3,
B) independent experiments performed in triplicate. *p < 0.05 as
compared with CSCs at the corresponding time-points.
Table 1 FDG uptake in CSCs, SAR-OS and MNNG/HOS
cells
Uptake (%/10
6)
Time (min) CSCs SAR-OS MNNG/HOS
15 1.86 ± 0.94* 4.16 ± 1.14 4.42 ± 1.47
30 2.01 ± 0.79* 6.39 ± 2.03 6.45 ± 2.19
60 2.94 ± 1.33* 11.27 ± 3.62 11.57 ± 3.55
Results are expressed as the mean ± standard deviation of four independent
experiments.
*p < 0.05 compared with SAR-OS and MNNG/HOS cells at the corresponding
time-points.
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with VER, whereas in MNNG/HOS (IC50 = 0.27 ± 0.02
μM) or SAR-OS (IC50 = 0.24 ± 0.05 μM) the IC50 values
did not differ significantly from those obtained without
VER (MNNG/HOS: IC50 = 0.30 ± 0.07 μM; SAR-OS:
IC50 = 0.26 ± 0.04 μM).
Sarcospheres have also shown enhanced survival fol-
lowing irradiation, compared to adherent-growing cells.
Cell survival curves and related parameters are pre-
sented in Figure 6 and Table 4, respectively. The surviv-
ing fraction of cells derived from sarcospheres was
clearly superior when compared with those derived from
adherent cells, in the wide range of tested doses. The
irradiation survival curve of sarcospheres showed a
shoulder in the initial portion of the curve (up to 2 Gy),
and the corresponding mean lethal dose (LD50)w a so f
7.96 ± 3.00 Gy, significantly higher than the one
observed in MNNG/HOS (3.36 ± 0.55 Gy, p < 0.05) and
differentiated progeny SAR-OS (3.12 ± 1.38 Gy, p <
0.05) cells, and without any apparent shoulder on their
survival curves. The a/b ratio, corresponding to the
dose where cell killing from linear and quadratic com-
ponents are equal, was of 18.6 Gy for sarcospheres,
significantly higher than the one obtained for adherent
cells.
Radiation induces ROS production in adherent cells
The intracellular levels of ROS induced by irradiation
were measured using the fluorescent dye H2DCF-DA.
The measurements were performed within the first 60
min following irradiation and normalized to the con-
trols. Both monolayer cultures (MNNG/HOS and SAR-
OS) showed a dose-dependent formation of ROS (Figure
7). In these cells the increase observed in ROS produc-
tion in relation to the non-irradiated cells was signifi-
cant, even for the lower irradiation dose used (2 Gy). In
opposite, irradiation did not induce a significant increase
in ROS production in sarcosphere-derived cells. These
results suggest that sarcospheres might have higher
intrinsic antioxidant capacity than their differentiated
progeny (SAR-OS) and MNNG/HOS cells, which may
contribute for their higher radioresistance.
Figure 4 Dose-response curves of CSC, SAR-OS and MNNG/HOS cells to DOX, CIS and MTX. Cells were incubated with different doses of
DOX (A), CIS (B) and MTX (C) during 48 hours. Cell survival was analyzed using the MTT assay. The mean IC50 values of all drugs in CSCs were
significantly higher (p < 0.05) than those in SAR-OS and MNNG/HOS cells. Data are presented as the mean ± standard deviation of five
independent experiments, performed in duplicate. The lines represent the fit to a sigmoid model.
Table 2 Uptake of FDG during differentiation of CSCs
Uptake (%/10
6)
Time (min) CSCs 5 days 12 days 19 days
15 1.86 ± 0.94 2.80 ± 0.64 2.95 ± 0.94* 3.68 ± 0.42*
30 2.01 ± 0.79 4.24 ± 1.00* 4.61 ± 1.62* 5.33 ± 1.21*
60 2.94 ± 1.33 7.10 ± 2.03* 8.93 ± 2.05* 10.14 ± 2.35*
Results are expressed as the mean ± standard deviation of three independent
experiments.
*p < 0.05 compared with CSCs at the corresponding time-points.
Table 3 IC50 values of chemotherapeutic drugs in CSCs,
SAR-OS and MNNG/HOS cells
IC50 (μM)
DOX CIS MTX
CSCs 0.80 ± 0.22* 14.71 ± 1.68* 0.050 ± 0.020*
SAR-OS 0.26 ± 0.04 7.96 ± 2.88 0.006 ± 0.001
MNNG/HOS 0.30 ± 0.07 6.61 ± 1.24 0.006 ± 0.001
Results are expressed as the mean ± standard deviation of five independent
experiments performed in duplicate. *p < 0.05 compared to SAR-OS and
MNNG/HOS cells Abbreviations:I C 50, half maximal inhibitory concentration;
DOX, doxorubicin; CIS, cisplatin; MTX, methotrexate. Cells were incubated with
increasing concentrations of DOX (0-60 μM), CIS (0-80 μM) and MTX (0-1000
μM) during 48 hours. The cytotoxicity was evaluated using the MTT
colorimetric assay and the IC50 were obtained from sigmoidal fitting of cell
survival curves.
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radiation exposure and induction of apoptosis
Analysis of cell cycle distribution was performed after 48
h of treating sarcospheres and adherent cells with che-
motherapeutic drugs and ionizing radiation, using PI
staining and flow cytometry. DOX and CIS, at doses
near the IC50 values, caused a G2/M cell cycle arrest in
a concentration-dependent manner in parental cells that
was accompanied by a proportional decrease in the per-
centage of cells in the G1 phase (Figure 8A, B). The
proportion of cells in the S phase was not significantly
altered by any of the drugs. The anti-metabolite MTX
that inhibits the synthesis of DNA, induced an arrest in
the MNNG/HOS cell population in the G1/S phase and
decreased the percentage of cells in the G2/M phase
(Figure 8C). Similar effects were observed in cell cycle
progression of SAR-OS cells (data not shown). In oppo-
site, none of the drugs altered significantly the cell cycle
distribution in sarcosphere-derived cells. To determine
whether chemotherapeutic agents induced apoptosis,
nuclei were stained with the Hoechst-33342 dye. The
results obtained showed that all drugs induced an
increase in chromatin condensation and formation of
apoptotic bodies in both MNNG/HOS and SAR-OS
adherent cells, for the tested doses. For sarcosphere-
derived cells, the morphological changes typical of apop-
tosis were less evident and only became visible at higher
dosages (Figure 8D-F).
Cell cycle analysis of irradiated adherent cells showed
a dose-dependent cell cycle-arrest at G2/M phase that
was accompanied by a proportional decrease of cells in
G1 phase. As observed with chemotherapeutic drugs,
Figure 5 Effects of VER on reversal of resistance to DOX in MNNG/HOS, sarcospheres and SAR-OS cells. Dose response curves of DOX in
the absence and in the presence of VER 10 μM. Data-points correspond to the mean ± standard deviation of at least three independent
experiments performed in triplicate.
Figure 6 Dose-response curves of CSC, SAR-OS and MNNG/HOS
cells to ionizing radiation. Exponentially growing cells were
irradiated in a linear accelerator, at doses ranging between 2 and 20
Gy. Cell survival was analyzed after 7 days using the MTT assay. The
LD50 for CSCs was significantly higher than that in SAR-OS and
MNNG/HOS cells. Data are presented as the mean ± standard
deviation of at least three independent experiments, performed in
triplicate. The lines represent the fit to a linear-quadratic model.
Table 4 Cell survival parameters of CSCs, SAR-OS and
MNNG/HOS cells after irradiation
Parameters CSCs SAR-OS MNNG/HOS
LD50 (Gy) 7.96 ± 3.00* 3.12 ± 1.38 3.36 ± 0.55
a (Gy
-1) 0.06411 0.10526 0.05421
b (Gy
-2) 0.00353 0.03482 0.04323
a/b (Gy) 18.16* 3.02 1.25
R
2 0.867 (n = 5) 0.999 (n = 3) 0.995 (n = 3)
Survival parameters were obtained from linear-quadratic model fitting of cell
survival curves. The LD50 values correspond to the mean ± standard deviation
of the indicated independent experiments, performed in triplicate. *p < 0.05
compared to SAR-OS and MNNG/HOS cells Abbreviations: LD50 - median lethal
dose, a - probability of occurrence of a double-strand break induced by one
ionizing particle, b - probability of two single-strand breaks combine and form
a double-strand break, a/b - dose corresponding to the probability of
occurrence of a double-strand break and the combination of two single-
strand breaks be the same, R
2 - Adjusted R-squared.
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cell cycle phase distribution of sarcosphere-derived cells
compared with sham-irradiated controls (Figure 9A).
Micrographs of Hoechst-33342 staining showed the for-
mation of apoptotic membrane blebbing and chromatin
condensation in MNNG/HOS and SAR-OS cells irra-
diated at doses of 4, 6 and 10 Gy. Focuses of chromatin
condensation in sarcospheres were only visualized with
extreme doses of irradiation (Figure 9B).
Discussion
In this study we aimed to identify the presence of puta-
tive CSCs in a human osteosarcoma cell line and to
evaluate their role in resistance to chemo- and radio-
therapy. Our findings provide evidence that this osteo-
sarcoma cell line contains a subpopulation of cells with
stem-like properties as demonstrated by the formation
of spherical clones in serum-free medium under ancho-
rage-independent conditions. These results are in accor-
dance with those previous reported by Gibbs et al. that
demonstrated the presence of stem-like cells in distinct
bone sarcomas when cultured in stressful growth condi-
tions [16]. This method has been widely used in the
prospective isolation of cells with stem-like properties
from several malignancies, and is particularly useful
when specific markers have not been identified, as is the
case of CSCs for most tumors [20-23].
The isolated cells were found to express MSC’s surface
markers CD73, CD90 and CD13 and were able to differ-
entiate into the osteoblastic, chondrocytic and adipocytic
lineages under standard culture differentiating condi-
tions, which indicates that they remain mesenchymal and
preserve some degree of the MSC’s plasticity. However,
the expression pattern of MSC-related antigens cannot
be used as a specific marker of stem-like cells in osteosar-
coma, since parental MNNG/HOS cells exhibited an
immunophenotype similar to that of sarcospheres. This
is in line with the theory that osteosarcoma originates
from a primitive MSC in a consequence of impaired dif-
ferentiation into osteoblasts that undergo malignant
transformation. Therefore it is conceivable that more dif-
ferentiated parental MNNG/HOS cells retain some prop-
erties of MSC, including the expression of cell surface
markers and that the overlap of immunophenotype mar-
kers is related with the stage of differentiation of MSCs
at the time of the mutation [24]. Moreover, after cultur-
ing in specific differentiation conditions, MNNG/HOS
cells differentiated towards osteoblasts, which indicate
these cells still have some propensity of the original line-
age. In addition, we found that cells derived from sarco-
spheres expressed high levels of Oct4 and Nanog (Figure
2C), which are key transcription factors required for the
maintenance of self-renewal and pluripotency of embryo-
nic stem cells (ES). These attributes of ES cells have regu-
larly been identified in subsets of stem-like cells derived
from mesenchymal tumors and of many other solid
tumors, and appear to be critical to the phenotype of
tumor-initiating cells [25-27].
Two other fundamental properties of cancer stem-like
cells are their ability to self-renew and to generate differ-
entiated progeny. The sphere-forming capacity of these
cells that was observed following three serial passages
under selective culture conditions demonstrated the pre-
sence of a self-renewing cell population within the
MNNG/HOS cell line. Furthermore, when transferred to
adherent plates and allowed to grow in serum-containing
medium, sarcospheres were able to expand in monolayer
acquiring the morphological features and biological beha-
vior of parental MNNG/HOS cells. We noticed that after
19 days in differentiating culture conditions, sarcosphere-
derived cells (SAR-OS cells) started to proliferate with
the same doubling-time as the MNNG/HOS cells around
24 h (data not shown), displayed similar glucose uptake
as assessed with FDG and showed a significant decrease
in the expression levels of the proteins associated with a
stem cell phenotype (Oct4 and Nanog) and of the ABC-
related transporters (Pgp and BCRP), reaching the levels
of parental MNNG/HOS cells. The degree of FDG accu-
mulation is considered a good indicator of the metabolic
status of tumor cells. This fluorinated glucose analogue is
widely used for detecting and staging of malignant
Figure 7 Reactive oxygen species production in CSC, SAR-OS
and MNNG/HOS cells following irradiation. Single-cell
suspensions were incubated with the fluorescent dye H2DCF-DA for
15 min in the dark. The levels of DCF fluorescence indicative of ROS
generation were monitored within the first 60 min following
irradiation (2-20 Gy) using a fluorescence microplate reader
(excitation: 498 nm, emission: 530 nm) and normalized to the
fluorescence values of sham-irradiated cells. Data represent
normalized mean fluorescence intensity ± standard deviation, of
three independent experiments performed in triplicate. Irradiation
did not generate significant increases in ROS production in CSCs (p
> 0.05) in relation to sham-irradiated cells. For adherent cells
significant increases (p < 0.05) were observed for doses above 8 Gy.
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tumor cells when compared to non-tumoral tissues
[28,29]. This increased accumulation of FDG is related to
a change in the metabolism of tumor cells that switches
from oxidative phosphorylation to glycolysis, even in the
presence of high levels of oxygen. This process, the so-
called Warburg effect, results in a much less efficient
mechanism for energy generation, and thus an increase
in the requirement for glucose uptake, but is important
in providing building blocks to support cancer cell prolif-
eration [30,31].
We found that sphere-forming cells, in comparison
with the parental MNNG/HOS cells, accumulated
significantly lower amount of FDG (Figure 3A). More-
over, after being placed in differentiation culture condi-
tions, we observed a marked and progressive increase in
the cellular uptake of FDG until reaching the values of
MNNG/HOS cells after 19 days (Figure 3B). This pro-
gressive increase in cellular FDG uptake indicates that
there are dynamic changes in glucose metabolism occur-
ring during the differentiation process and that undiffer-
entiated cells, as stem like-cells, are likely to have low
energy requirements. This could be related with the fact
that this fraction of cells is entering into a quiescent sta-
t u sa n dd i v i d e si n f r e q u e n t l y. This is in line with pre-
vious studies suggesting that quiescent cells reduce their
Figure 8 Cell cycle and apoptotic responses of MNNG/HOS and CSCs to chemotherapeutic agents.R e p r e s e n t a t i v ec e l lc y c l ep h a s e
distribution and Hoescht-33342 nuclear staining of MNNG/HOS and CSCs after treatment with doxorubicin (A, D), cisplatin (B, E) and methotrexate
(C, F). Cells were incubated with drugs at the indicated concentrations. After 48 h, cells were fixed and stained with propidium iodide for cell cycle
analysis by FACS and with the DNA Hoescht-33342 dye to detect apoptosis. All drugs induced a cell cycle arrest and chromatin condensation in
MNNG/HOS cells. In contrast, there were no significant changes in cell cycle distribution of CSCs and a few apoptotic cells were detected for the
high drug concentrations. Fluorescence images were acquired using a fluorescence microscope with an original Magnification of × 630.
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highly proliferative cells [32].
Some studies have shown that stem cells can become
quiescent without losing their proliferative potential [14].
This has been referred as an intrinsic defense mechanism
of CSCs that they use against chemotherapeutic drugs tar-
geting rapidly dividing cells [33]. As a result, at least some
of the stem-like cells are able to survive and be responsible
for tumor regrowth after therapy. The lower FDG accu-
mulation by stem-like cells can have important clinical
implications, as PET imaging with FDG is commonly used
for monitoring tumor response to therapy, by measuring
changes in FDG uptake. In general, tumors with low accu-
mulation of FDG after therapy are considered to be a
good prognostic factor. Based on our observations, this
reading can be biased by the fact that surviving stem-like
cells might be few in number and might not accumulate
FDG efficiently due to their quiescence, a status that can
be maintained for a defined period before they return to a
proliferative state and initiate tumor recurrence.
The enhanced tumorigenic ability of sarcospheres was
demonstrated in vivo in immunocompromised mice. The
animals injected with 100,000 sphere-derived cells devel-
oped massive tumors with approximately 150 mm
3 of
volume at 4 weeks, whereas the injection of the same
number of MNNG/HOS cells induced tumors with a 7-
fold lower volume (approximately 20 mm
3). Based on
previous studies, the injection of few stem-like cells
derived from mesenchymal neoplasms can be responsible
t oi n i t i a t eat u m o rd u et ot h e i re n h a n c e dc a p a c i t yf o r
self-renewal and a more plastic capacity that enables
them to adapt to the stringent environment of the xeno-
grafts [30,34]. It seems reasonable that the tumors arising
from the MNNG/HOS cells results from the presence of
a subset of stem-like cells that are sufficient to initiate
tumor formation.
The chemo- and radiosensitivity assays clearly demon-
strated the higher resistant profile of spherical clones
when compared with parental MNNG/HOS cells. The
mean IC50 values of all tested drugs (DOX, CIS and MTX)
in sarcospheres were significantly higher (up to three to
four-fold) than those obtained in adherent MNNG/HOS
and SAR-OS cells (Table 3). One of the mechanisms that
have been proposed to explain the chemoresistance of
CSCs is the activity of certain ABC transporters that med-
iate drug efflux, preventing the intracellular accumulation
of chemotherapeutic agents at toxic levels. The up-regula-
tion of these transporters has been observed in CSCs of
several malignancies and is also the basis for the Hoechst-
33324 dye exclusion assay to isolate a side-population (SP)
enriched with cancer stem-like cells in cell lines and
tumor samples [35]. Our data demonstrated a significant
high expression of Pgp and BCRP in spherical colonies
compared with parental cells (Figure 2C), which might
explain the higher resistance of CSCs to DOX and MTX,
since these drugs are substrates of those transporters
[12,36]. The reversal of resistance to DOX that was
observed in sarcospheres after co-incubation with VER
sustains this hypothesis. It has long been known that VER
restores drug accumulation sensitizing resistant tumor
cells through inhibition of drug efflux pumps [37]. VER is
a non-specific inhibitor of ABC transporters and is itself a
transport substrate of Pgp and BCRP competing with
drugs for the transporter, blocking the efflux of the che-
motherapeutic agent. Therefore is seems reasonable that
both proteins are functionally active and contribute for the
drug resistance phenotype of CSCs, at least to DOX which
is the main chemotherapeutic drug used in the treatment
of osteosarcoma.
In addition to an increased capacity for drug efflux,
other mechanisms may co-exist, like alterations in cell
cycle, enhanced DNA repair capacity, reduced apoptosis
Figure 9 Cell cycle and apoptotic responses of MNNG/HOS and
CSCs to irradiation. Representative cell cycle phase distribution (A)
and Hoescht-33342 nuclear staining (B) of MNNG/HOS and CSCs
after irradiation at indicated doses. Forty-eight hours after irradiation,
cells were fixed and stained with propidium iodide (PI) for cell cycle
analysis by flow cytometry and with the DNA Hoescht-33342 dye to
detect apoptosis. Irradiation induced a dose-dependent cell cycle
arrest at G2/M phase and apoptosis in MNNG/HOS cells and had no
significant effects on cell cycle progression in CSCs with minimal
induction of apoptosis. Fluorescence images were acquired using a
fluorescence microscope with an original magnification of × 630.
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[38]. High activity of the detoxification enzyme aldehyde
dehydrogenase (ALDH1) has been found in osteosar-
coma CSCs as well as in other solid tumors, and is
referred as a possible drug resistance mechanism for
both normal and malignant stem cells [39,40]. This
enzyme is responsible for the oxidation of intracellular
aldehydes, thereby mediating self-protection and resis-
tance to some alkylating agents (e.g. cisplatin) used in
cancer treatments [41].
The ability of stem-like cells to enter in a quiescent or
slow-dividing state can also contribute for their resis-
tance to conventional therapies that target proliferating
cells. The low energy requirement evidenced by the
small accumulation of FDG in sarcospheres is consistent
with a slow dividing rate of these cells. Likewise, the
mean LD50 values obtained from irradiation cell-survival
curves were significantly superior for sarcospheres as
compared with adherent cells (Table 4). The survival
curves of sarcospheres clearly showed a shoulder at
lower and, therefore, clinically relevant doses of irradia-
tion, which is probably due to an enhanced capacity to
repair potential lethal damages. In contrast, no obvious
shoulder was observed in both adherent MNNG/HOS
and SAR-OS cells. This is consistent with the higher a/
b ratio that was obtained for sarcospheres (18.16 Gy)
compared to that of the MNNG/HOS cells (1.25 Gy). In
general, cells displaying high a/b ratios are more resis-
tant to cell dead induced by lethal DSB and have an
enhanced capacity of DNA repair [42]. It is well estab-
lished that cell killing after exposure to ionizing radia-
tion is partially mediated by free radicals. Consistent
with the increased radioresistance, were the decreased
production of ROS levels in sarcosphere-derived cells,
compared with adherent counterparts (Figure 7), poten-
tially as a result of increased levels of free radical sca-
vengers (e.g., glutathione and superoxide dismutases).
These results are in agreement with previous data
reported by others in cancer-initiating cells of brain
tumors [43] and breast cancer [44,45]. They found that
stem cell-enriched subpopulations contained low levels
of ROS and developed less DNA damages compared
with non-stem counterparts, and that those low levels of
ROS were associated with increased expression of free
radical scavenging systems. Notably, the depletion of
ROS scavengers, via pharmacological depletion of glu-
tathione, increased the radiosensitivity of breast CSCs,
which demonstrated the importance of anti-oxidative
defenses in radioresistance and survival of stem-like
cells. The general low ROS concentration found in nor-
mal tissue stem cells, compared with their cellular des-
cendants suggests that stem cells have conserved this
attribute for protecting their genome from endogenous
and exogenous ROS-mediated damage [45].
The absence of significant alterations in cell cycle pro-
gression of sarcospheres following irradiation and drug
exposure as well, suggests that they possess highly acti-
vated basal DNA repair mechanisms and possibly
enhanced efficiency on DNA damage response activity
that restrain them from undergoing apoptosis. In fact,
we observed that sarcospheres are less susceptible to
apoptosis as compared with parental MNNG/HOS cells,
since the typical signs of apoptosis were only visible for
higher doses of irradiation and drugs. Both treatments
induced apoptosis and a G2/M cell cycle arrest in a
dose-dependent manner in adherent cells indicating a
cellular response to DNA-induced damages.
Our results are in line with previous findings observed
in CSCs isolated from mesenchymal neoplasms showing
increased chemoresistance with respect to their adherent
counterparts [46-48]. Such limited effectiveness of stan-
dard therapies suggests that they possess innate resis-
tance mechanisms allowing them to survive and initiate
tumor recurrence. The high levels of Pgp/BCRP expres-
sion and the relative quiescence observed in sarco-
spheres compared with the bulk population come out as
potential resistance mechanisms operating in osteosar-
coma stem-like cells. Nevertheless we cannot exclude
other mechanisms such as the up-regulation of anti-
apoptotic and down-regulation of pro-apoptotic path-
ways, as well as active DNA repair that can contribute
to the overall resistance of CSCs to standard therapies.
Conclusions
Our study provides strong evidence that MNNG/HOS
osteosarcoma cell line is enriched in CSCs with
enhanced tumorigenic potential and increased resistance
to conventional therapies. The relatively higher resis-
tance of CSCs to the main chemotherapeutic agents
recommended by EURAMOS-1 might contribute to the
currently static survival rate observed in osteosarcoma
patients. Further studies in CSCs derived from patients’
specimens are needed for a continued clarification of
the role of these cells in therapy response and therefore
to contribute for the establishment of novel therapeutic
strategies.
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